Navigation Links
Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
Date:5/23/2019

Catalent (Booth 3101), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to launch its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention, which takes place at the Pennsylvania Convention Center in Philadelphia, from June 3-6, 2019.

OneBio has been designed specifically to address the challenges facing biologic development companies that are looking to accelerate programs to clinic or market, or that require greater simplicity in the development process, including fewer internal resource needs and a reduced risk of rework. As a single, integrated provider, Catalent Biologics’ OneBio Suite will aim to reduce timelines, risk and complexity by providing customers with a single contract, program manager, and development timeline from cell line to clinical supply with harmonized quality systems. The OneBio Suite draws upon Catalent’s proven track record of progressing biologic drugs to market, which includes over 115 global clinical trials and 11 commercially marketed monoclonal antibodies using the company’s GPEx® cell line development technology, and 20 approved products through fill/finish and commercial supply to global markets.

“Time is often lost for sponsors on the path to clinic from contract negotiation, site inspections, handoffs, and poor communication between multiple vendors,” commented Bernie Clark, Vice President, Marketing & Strategy, Catalent Biologics & Specialty Drug Delivery. “Through our new OneBio Suite, Catalent is uniquely positioned to provide an integrated offering that can accelerate biologic development potentially shaving weeks to months off standard timelines and allowing our customers to get to clinic and market faster.”

Additionally, at the BIO Convention, Steven Hager, Ph.D., Senior Director, Technical Support, will present ‘Cell Line Development Strategies for Difficult to Express Proteins’ as part of the ‘Emerging Techniques, Technologies and Strategies’ track. His presentation takes place on Wednesday, June 5 from 11:40 a.m.-12:00 p.m. at the BPI Theater, Booth #3211 in the BioProcess Zone.

On the same day, from 1:45-2:30 p.m., Dr. Hager will also participate in a ‘Single Use Systems Versus Stainless Steel’ roundtable, also at the BPI Theater.

Catalent Biologics provides advanced technologies and integrated solutions for biologic and biosimilar development and manufacturing, from DNA to fill/finish and commercial supply, through its extensive Biologics network including: Bloomington, Indiana, where the company recently announced a twentieth commercial launch of a fill/finish product, and; Madison, Wisconsin, home of Catalent Biologics’ proprietary GPEx technology for stable, high-yielding mammalian cell lines with eleven approved molecules. For more information on Catalent Biologics, visit biologics.catalent.com.

Notes for Editors
About Catalent Biologics
Catalent Biologics has 20+ years’ experience in development, manufacturing, and analytical services for new biological entities, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials and 11 marketed products have used GPEx® cell line engineering technology. A further 20 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to patients, faster. For more information, visit biologics.catalent.com.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_launch_onebio_suite_for_integrated_biologics_development_manufacturing_and_supply_at_bio_international_2019/prweb16333539.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
2. Catalent Receives P&G External Business Partner of the Year Award
3. Zer0 to 5ive Turns 20; Celebrates with Launch of New Startup Package
4. ASGCT Launches Clinical Trials Finder on Clinical Trials Day 2019
5. Akadeum Launches Seven New Products at Immunology 2019 Conference in San Diego
6. FISO Technologies Launches the FOP-M200, the Smallest Commercially Available Pressure Transducer
7. Medpricer Adds Rich Data Extraction to Portfolio of Services with Launch of mSource® AI Contract Text Analysis
8. Swiss Biotech Gnubiotics, Announces Global Launch of GNU100 the First Microbiome Specialty Ingredient for Companion Animal Gut Health
9. SeqOnce Biosciences Launches RhinoSeq™ Rapid DNA Library Preparation Kit
10. FileWave Launches New Channel Partner Program
11. FEITIAN Technologies Launches Two New Payment Card Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... (PRWEB) , ... August 24, 2020 , ... ... for the treatment of chronic inflammatory and fibrotic diseases, today announced that Dr. ... President of Drug Discovery. , Dr. Canan previously served as Executive Director of ...
(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, a biopharmaceutical cold chain ... 5000 list. The list is the most prestigious ranking of the nation’s fastest-growing private ... this year’s list, reported three-year revenue growth of 71 percent. , The Inc. ...
(Date:8/21/2020)... ... 19, 2020 , ... “How can we help?”, asks Hans ... Bioscience for more than twenty years. Together with Douglas Granger, Ph.D., founder of ... Foundations of Interdisciplinary Saliva Research and Applications ," and Steven Granger, Ph.D., Chief ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... , ... July 29, 2020 , ... R3 Stem Cell ... for only $3950. With 50 million stem cells total, patients may choose which extremities ... therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord ...
(Date:7/31/2020)... N.J (PRWEB) , ... July 29, 2020 , ... ... company, and Catalent, the leading global provider of advanced delivery technologies, development, and ... today announced that they have entered into a strategic partnership whereby Catalent will ...
(Date:7/22/2020)... ... 2020 , ... Join experts from Reed Tech , Gary Saner, Sr. ... one hour live webinar on Thursday, August 13, 2020 at 11am EDT ... medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical device ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra ... life sciences and food industries, is pleased to announce that Charles Galea has ... Business Development. , Charles is an accomplished and results-driven sales executive with over ...
Breaking Biology Technology: